07:50 AM EDT, 08/14/2025 (MT Newswires) -- Beam Therapeutics ( BEAM ) said Thursday the US Food and Drug Administration has granted regenerative medicine advanced therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease.

The company said that this designation is designed to support the development and evaluation of regenerative medicines, including genetic therapies, with the intent of addressing serious or life-threatening diseases that have unmet medical needs.

Beam Therapeutics ( BEAM ) shares were up 3.3% in recent premarket activity Thursday.